Melanoma

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
Jieqing Chen, Caitlin Creasy, Carlos Antonio Torres-Cabala, Suhendan Ekmekcioglu, Sourindra N Maiti, Charuta Kale, Cara Haymaker, Jason Roszik, Roland L Bassett, Jianhua Hu, Zhiqiang Wang, Wencai Ma, R Eric Davis, Chantale Bernatchez, Patrick Hwu, Laszlo Radvanyi

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P243; DOI: 10.1186/2051-1426-2-S3-P243
Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
Stefani Spranger, Riyue Bao, Thomas Gajewski

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) O15; DOI: 10.1186/2051-1426-2-S3-O15
Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
Rikke Andersen, Marco Donia, Troels Holz Borch, Eva Ellebæk Steensgaard, Trine Zeeberg Iversen, Per Kongsted, Mads Hald Andersen, Per thor Straten, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P1; DOI: 10.1186/2051-1426-2-S3-P1
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Robert HI Andtbacka, Frances A Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith Delman, Lynn Spitler, Igor Puzanov, Sanjiv Agarwala, Mohammed Milhem, Kevin Harrington, Mark Middleton, Ai Li, Mark Shilkrut, Robert Coffin, Howard Kaufman

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P263; DOI: 10.1186/2051-1426-2-S3-P263
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Elixabet Bolaños-Mateo, Bettina Weigelin, Alvaro Teijeira, Ivan Martinez-Forero, Sara Labiano, Arantza Azpilicueta, Aizea Morales-Kastresana, Jose I Quetglas, Esther Wagena, Alfonso Rodriguez, Lieping Chen, Peter Friedl, Ignacio Melero

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P95; DOI: 10.1186/2051-1426-2-S3-P95
In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
Zachary S Morris, Emily Guy, David Francis, Monica Gressett, Richard Yang, Alexander Rakhmilevich, Jaquelyn Hank, Stephen Gillies, Paul Harari, Paul Sondel

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P160; DOI: 10.1186/2051-1426-2-S3-P160
Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma
Ayelet Sivan, Leticia Corrales, Thomas Gajewski

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) O11; DOI: 10.1186/2051-1426-2-S3-O11
IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
Hilary Bilyard, Charlotte Mines, Laura Rosa Brunet, Angus Dalgleish, Frances Macintosh

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P83; DOI: 10.1186/2051-1426-2-S3-P83
Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, Taha Merghoub, Jedd D Wolchok

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P212; DOI: 10.1186/2051-1426-2-S3-P212
A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
Susan Knox, Sunil Reddy, Susan M Hiniker, Susan Swetter, Lei Shura, Holden T Maecker

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P75; DOI: 10.1186/2051-1426-2-S3-P75

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages